Skip to main
PODD
PODD logo

Insulet (PODD) Stock Forecast & Price Target

Insulet (PODD) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 53%
Buy 41%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

Insulet's stock outlook is bolstered by projected revenue growth, with an expected increase from $2.7 billion in FY25 to $4.2 billion by FY28, reflecting a compound annual growth rate (CAGR) of 16.3%. The company has raised its total sales growth guidance for 2025 to 28-29% year-over-year, indicating strong operational performance and market penetration potential in the under-served diabetes market. Furthermore, improvements in gross margin to +71% and operational margin forecasts of 17.3-17.5%, alongside an innovative pipeline, position Insulet for sustained profitability and shareholder value enhancement.

Bears say

Insulet faces significant challenges, reflected in a projected decline of 85-95% in Drug Delivery revenue, indicating a major setback from prior expectations of a 92.7% drop. Additionally, a weaker-than-expected expansion into the U.S. market raises concerns about the company's ability to drive product adoption amid increasing competitive pressures and macroeconomic headwinds. This situation is compounded by risks associated with regulatory hurdles and the potential for insufficient coverage and reimbursement from third-party payers, threatening Insulet's overall growth trajectory and earnings power.

Insulet (PODD) has been analyzed by 17 analysts, with a consensus rating of Buy. 53% of analysts recommend a Strong Buy, 41% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insulet and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insulet (PODD) Forecast

Analysts have given Insulet (PODD) a Buy based on their latest research and market trends.

According to 17 analysts, Insulet (PODD) has a Buy consensus rating as of Dec 11, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $367.59, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $367.59, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insulet (PODD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.